RXRX
Recursion Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.63
+5.52%Margins
Gross margin
-46.7%
EBITDA margin
-810.2%
EBIT margin
-991.7%
Net margin
-945.9%
FCF margin
-645.8%
-56.7%
Return on equity
-42.8%
Return on assets
-55.7%
Return on invested capital
0.04x
Asset turnover
-$350.5M
Cash from operations
$1.02
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026